Figure 7.

KA and anthralin synergize with LRAs from multiple functional classes in vitro. A, effects of 3 μm KA on latency reversal in J-Lat 9.2 cells in the presence of 10 μm prostratin, 0.1 μm panobinostat, 10 ng/ml TNFα, 0.7 μm JQ1, and 1 μm Aza-Cdr. B, extent of synergism in J-Lat 9.2 cells treated with KA plus control LRAs in A, as measured by the Bliss independence model. C and D, effects of 10 μm anthralin on latency reversal (C) and synergism (D) in J-Lat 9.2 cells in the presence of control LRAs. Data are arrayed as described in A and B. E and F, effects of KA and anthralin on latency reversal (E) and synergism (F) in the presence of 10 μm prostratin. In E, “0” on the x axis indicates the activity of 10 μm prostratin in the absence of KA or anthralin. Data shown for 10 μm prostratin plus 3 μm KA or 10 μm anthralin are the same data shown in A–D. *, p < 0.05; **, p < 0.01 between the observed and predicted responses assuming strictly additive effects (i.e. Bliss independence model-based synergism) from at least four independent experiments. Error bars, S.D.